GlycoFi, acquired by Merck Pharma, was early stage research and development company that focused on the production of human therapeutic recombinant proteins.

The company was developing a novel approach to express human genes in a genetically altered stain of yeast cells. The GlycoFi approach was safer and more efficient in comparison to other expression systems and had the ability to provide its customers with shorter drug development cycles, longer exclusivity selling periods, more reliable drugs and lower costs.

Contact Info

21 Lafayette Street, Suite 200, Lebanon, NH, 03766
Tel: (603) 643-8186

Polaris Lead

Terry McGuire